Retatrutide: Preclinical Research Overview
What is Retatrutide?
A peptide is a short chain of amino acids — the same building blocks that make up proteins — engineered to interact with specific biological receptors. Retatrutide (also known as LY3437943, developed by Eli Lilly) is a synthetic peptide designed to act simultaneously on three separate receptor types in the body: the GLP-1 receptor, the GIP receptor, and the glucagon receptor.
The term triple agonist describes this precisely: the compound activates (agonises) all three receptor pathways at once, rather than just one or two. Each of these three receptors plays a distinct role in metabolic signalling — how the body regulates energy, glucose, and fat. By engaging all three simultaneously, Retatrutide represents a more complex pharmacological approach than earlier single or dual-receptor compounds.
The three receptor pathways Retatrutide engages are:
- GLP-1 (Glucagon-Like Peptide-1) — a gut hormone receptor involved in insulin secretion, appetite regulation, and gastric motility in preclinical models
- GIP (Glucose-Dependent Insulinotropic Polypeptide) — a receptor found in fat tissue and pancreatic beta cells, studied for its role in fat metabolism and insulin response in animal models
- Glucagon receptor — involved in hepatic glucose output and energy expenditure in preclinical research
Retatrutide has progressed further through clinical study than most research peptides in this class. It has been investigated in both Phase 1 and Phase 2 clinical trials, with data published in the New England Journal of Medicine, The Lancet, and Cell Metabolism. This depth of published data makes it one of the most academically documented peptides currently available for incretin & receptor research.
Velox Peptides supplies Retatrutide as a lyophilised powder for in vitro research use only, HPLC-verified at ≥98.8% purity, with third-party HPLC verification. Batch documentation is available on request. View the Retatrutide product page →
Receptor Mechanisms in Preclinical Research
Understanding Retatrutide's pharmacological profile requires understanding each of its three receptor targets independently before considering how they interact. The following summaries draw from peer-reviewed preclinical literature.
GLP-1 Receptor Pathway
GLP-1 (Glucagon-Like Peptide-1) receptors are found throughout the body — in pancreatic beta cells, the central nervous system, the gastrointestinal tract, and peripheral tissues. In animal models, activation of GLP-1 receptors is associated with increased insulin secretion in a glucose-dependent manner (meaning the effect is tied to circulating glucose levels), reduced gastric emptying, and appetite-suppression signalling in the hypothalamus.[4]
The GLP-1 receptor pathway has been extensively studied across rodent models and non-human primates, and GLP-1 receptor agonism forms the foundational mechanism of the most widely researched metabolic peptide class. Retatrutide incorporates this activity as one of its three simultaneous mechanisms.
GIP Receptor Pathway
GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors are expressed in pancreatic beta cells, adipose tissue (fat cells), bone, and the brain. In preclinical studies, GIP receptor activation is associated with enhanced insulin secretion and, critically, effects on fat tissue metabolism — including fat storage and lipolysis signals in rodent models.
Research interest in combining GIP and GLP-1 agonism stems from evidence that the two pathways may act synergistically rather than redundantly. Finan et al. demonstrated in rodent, primate, and early human studies that unimolecular dual GIP/GLP-1 agonists produced metabolic outcomes exceeding either mechanism alone.[2] Retatrutide builds on this dual-agonist foundation by adding glucagon receptor engagement as a third axis.
Glucagon Receptor Pathway
Glucagon receptors are expressed primarily in the liver (hepatocytes), where they regulate hepatic glucose output — the process by which the liver releases stored glucose into the bloodstream. Glucagon receptor activation also appears to influence energy expenditure in animal models, with some data suggesting increased thermogenesis.
In isolation, glucagon receptor activation raises blood glucose — the opposite of what GLP-1 agonism achieves. The rationale for including glucagon receptor activity in a triple agonist is the hypothesis that, when combined with GLP-1 and GIP agonism, the net metabolic effect on energy expenditure and fat metabolism may be greater than GLP-1/GIP agonism alone, while the glycaemic impact is modulated by the simultaneous insulin-secretion effects of the GLP-1 and GIP pathways.[5] This hypothesis was a key driver of Retatrutide's development and clinical investigation.
Key Study Findings
The following summaries are drawn from published peer-reviewed research. All findings are framed as observations from the respective studies and should not be interpreted as clinical recommendations. Retatrutide is not approved for human use and is supplied for in vitro research only.
This Phase 2 randomised controlled trial enrolled 338 participants across multiple dose cohorts over 48 weeks. The study investigated retatrutide at doses ranging from 1mg to 12mg weekly. Researchers observed substantial reductions in mean body weight across the higher-dose groups at both the 24-week and 48-week assessments, with the largest reductions in the 12mg cohort. The study reported a tolerability profile broadly consistent with other GLP-1 class compounds, with gastrointestinal adverse events (nausea, vomiting, diarrhoea) reported most frequently in the early dose-escalation period. The authors concluded that further Phase 3 investigation was warranted.
Important note: This is human clinical trial data, not preclinical animal study data. Results in human trials do not necessarily predict in vitro or animal model outcomes, and vice versa.
PMID: 37352492 — NEJM 2023;389(6):514–526
This study characterised LY3437943 in rodent models and non-human primates prior to human trials. Researchers reported receptor binding affinity data demonstrating activity at all three receptor targets (GIP, GLP-1, glucagon), with selective potency profiles at each. In diet-induced obese mouse models, the study observed significant reductions in body weight, improvements in glucose tolerance parameters, and changes in lipid profiles compared to vehicle controls. Non-human primate data demonstrated pharmacokinetic properties consistent with once-weekly dosing, with a half-life supporting weekly administration. The study described LY3437943 as the first characterised triple GIP/GLP-1/glucagon receptor agonist to advance toward clinical development.
PMID: 35108511 — Cell Metab. 2022;34(6):882–898.e6
This Phase 1b multicentre, double-blind, placebo-controlled study investigated LY3437943 in participants with type 2 diabetes to characterise safety, tolerability, and pharmacokinetics at escalating doses. Researchers observed a mean half-life of approximately 7 days, consistent with once-weekly dosing. Pharmacokinetic modelling confirmed dose-proportional exposure across the studied dose range. Receptor engagement was confirmed biochemically. The study reported an adverse event profile consistent with GLP-1 class compounds, with no serious unexpected safety signals at doses studied. The authors noted the pharmacokinetic profile supported advancement to Phase 2 investigation.
PMID: 36356631 — Lancet. 2022;400(10366):1869–1881
How Retatrutide Differs From Other Research Peptides
The development of Retatrutide represents a progression from earlier single and dual-receptor compounds in incretin & receptor research. The table below summarises the receptor targeting profile of the three most clinically investigated compounds in this class.
| Mechanism | Semaglutide | Tirzepatide | Retatrutide (LY3437943) |
|---|---|---|---|
| GLP-1 receptor agonism | ✓ | ✓ | ✓ |
| GIP receptor agonism | ✗ | ✓ | ✓ |
| Glucagon receptor agonism | ✗ | ✗ | ✓ |
| Receptor targets | 1 | 2 | 3 |
| Research generation | First generation | Second generation | Third generation (triple) |
Retatrutide represents a newer research class than single or dual-receptor GLP-1 compounds. The addition of glucagon receptor agonism to the established GLP-1/GIP dual agonist model introduces a third mechanistic axis — hepatic glucose and energy expenditure modulation — that is absent from earlier-generation research peptides. This triple receptor engagement profile makes Retatrutide of significant academic interest in current incretin & receptor research, particularly for researchers investigating the relative contribution of each receptor pathway to observed metabolic outcomes.
Velox Peptides Supply Information
Retatrutide is supplied as a research reagent only. It is not a medicinal product and has not been evaluated by the MHRA or FDA. Not for human or veterinary consumption. See our Research Use Policy.
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514–526. PMID: 37352492
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(6):882–898.e6. PMID: 35108511
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a Phase 1b, multicentre, double-blind, placebo-controlled, randomised study. Lancet. 2022;400(10366):1869–1881. PMID: 36356631
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. PMID: 30120083
- Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749–757. PMID: 19597484
Frequently Asked Questions
What is Retatrutide?
Retatrutide (LY3437943) is a synthetic peptide that acts as a triple agonist at GLP-1, GIP and glucagon receptors simultaneously. It was developed by Eli Lilly and has been studied in Phase 1 and Phase 2 clinical trials, making it one of the most clinically investigated research peptides in the triple agonist class. It is supplied by Velox Peptides for in vitro research use only.
What does triple agonist mean?
A triple agonist activates three different receptor types at once. Retatrutide activates GLP-1 receptors, GIP receptors and glucagon receptors — each involved in different aspects of metabolic signalling in preclinical research models. This distinguishes it from semaglutide (single agonist) and tirzepatide (dual agonist) as a third-generation research compound in this class.
How does Retatrutide differ from semaglutide or tirzepatide?
Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 and GIP). Retatrutide targets all three — GLP-1, GIP and glucagon — making it a newer generation triple agonist and of significant interest in current incretin & receptor research. The addition of glucagon receptor agonism introduces a third mechanism (hepatic glucose output and energy expenditure modulation) not present in dual-agonist compounds.
What purity is Velox Peptides Retatrutide?
Velox Peptides Retatrutide is HPLC-verified at ≥98.8% purity. Batch documentation is available on request. To request a copy prior to ordering, email veloxpeps@gmail.com.
Is Retatrutide legal to buy in the UK?
Yes. Retatrutide is legal to purchase in the UK for in vitro research purposes. It is not licensed as a medicine and is not approved for human use. Velox Peptides supplies Retatrutide strictly as a research reagent in accordance with our Research Use Policy — not for human or veterinary consumption.
What form does Velox Peptides Retatrutide come in?
Retatrutide is supplied as lyophilised (freeze-dried) powder in 10mg and 20mg vials. It requires reconstitution with bacteriostatic water before use in research applications. Our reconstitution calculator can assist with concentration calculations.
